Paper Details

  1. Home
  2. Paper Details

A novel bile acid analog, A17, ameliorated non-alcoholic steatohepatitis in high-fat diet-fed hamsters.

Author: DengQiangqiang, GuoShimeng, JiangHaowen, NiuJunxing, PanGuoyu, PengHuige, PengZhaoliang, WangYing, XuanLijiang, XueYaru, ZhuYao

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Bile acids, key regulators of lipid metabolism, have potential as drug candidates for non-alcoholic steatohepatitis (NASH). This study investigated the anti-NASH effects of a novel bile acid analog, A17. A17 was found to reduce lipid accumulation in hepatocytes by inhibiting fatty acid uptake and promoting fatty acid oxidation. It also reduced inflammation in immune cells. In vivo studies in hamsters demonstrated that A17 improved liver pathology and reduced side effects compared to obeticholic acid, a currently approved NASH treatment. These findings suggest that A17 could be a promising new therapeutic option for NASH.
Paper Details　
Original Abstract of the Article :
Being endocrine signaling molecules that regulate lipid metabolism and affect energy balance, bile acids are potential drug candidates for non-alcoholic steatohepatitis (NASH). Obeticholic acid (OCA) could improve NASH accompanied by significant side effects. Therefore, it is worthwhile to develop s...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.taap.2020.115169

データ提供：米国国立医学図書館（NLM）

A Novel Bile Acid Analog, A17, Shows Promise in Ameliorating Non-Alcoholic Steatohepatitis (NASH)

Non-alcoholic steatohepatitis (NASH) is a serious liver disease, and finding effective treatments remains a challenge. This [study] investigates the potential of a novel bile acid analog, A17, in ameliorating NASH in hamsters. The authors explore the mechanisms by which A17 exerts its beneficial effects on NASH, providing insights into the potential of bile acid analogs as therapeutic agents.

A17: A Potential Oasis in the Desert of NASH Treatment

The study's results suggest that A17 holds promise as a therapeutic agent for NASH. A17 [improved liver pathological conditions] in hamsters with NASH, indicating its potential to reduce liver damage and inflammation. The authors identified several molecular mechanisms underlying A17's beneficial effects, including the reduction of fatty acid uptake, the stimulation of fatty acid oxidation, and the alleviation of inflammation.

Implications for NASH Treatment and Research

This study provides valuable insights into the potential of bile acid analogs as a therapeutic strategy for NASH. The promising results with A17 warrant further investigation to assess its long-term efficacy and safety in humans. This research underscores the importance of exploring novel therapeutic approaches for NASH, a growing public health concern.

Dr. Camel's Conclusion

This research is like discovering a new oasis in the desert of NASH treatment. The promising results with A17 offer hope for a more effective and potentially safer treatment option for this complex liver disease. Further research is crucial to unlock the full potential of bile acid analogs in combating NASH and improving patient outcomes.
Date :
  1. Date Completed 2021-01-06
  2. Date Revised 2021-01-06
Further Info :

Pubmed ID

32738331

DOI: Digital Object Identifier

10.1016/j.taap.2020.115169

Related Literature

Article Analysis
・Side Effects of obeticholic acid
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.